{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:57:05Z","timestamp":1791619025135,"version":"4.3.4"},"reference-count":86,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diabetic Kidney Disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Among individuals with type 1 diabetes mellitus (T1DM), 30\u201340% are at risk of developing DKD. This review focuses on the mechanistic processes, available and emerging biomarkers for diagnosing, monitoring, and preventing DKD, as well as treatment options targeted at DKD patients. A literature search was conducted on PubMed and Scopus using specific keywords. Inclusion and exclusion criteria were applied to select the articles used for this review. The literature highlights various mechanisms involved in the progression of DKD to more severe stages. Additionally, several biomarkers have been identified, which aid in diagnosing and monitoring the disease. Furthermore, numerous treatment approaches are being explored to address the underlying causes of DKD. Advanced research is exploring new medications to aid in DKD remission; sodium-glucose cotransport (SGLT2) inhibitors and finerenone, in particular, are gaining attention for their novel renoprotective effects. DKD is a major complication of diabetes, marked by complex and multifactorial mechanisms. Thus, understanding these processes is essential for developing targeted therapies to potentially reverse DKD progression. Biomarkers show promise for early diagnosis and monitoring of disease progression, while current treatment strategies underscore the importance of a multifaceted approach.<\/jats:p>","DOI":"10.3390\/jcm14030727","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:49:54Z","timestamp":1737611394000},"page":"727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4393-2252","authenticated-orcid":false,"given":"Jean Paule","family":"Joumaa","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Raffoul","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Sarkis","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Chatrieh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Zaidan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Attieh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-1619","authenticated-orcid":false,"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-2090","authenticated-orcid":false,"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.ackd.2017.12.005","article-title":"Acute Kidney Injury and Progression of Diabetic Kidney Disease","volume":"25","author":"Yu","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","article-title":"Epigenetics and epigenomics in diabetic kidney disease and metabolic memory","volume":"15","author":"Kato","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155237","DOI":"10.1016\/j.prp.2024.155237","article-title":"Deciphering the role of MicroRNAs in diabetic nephropathy: Regulatory mechanisms and molecular insights","volume":"256","author":"Abdelmaksoud","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trsl.2023.11.002","article-title":"Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review","volume":"265","author":"Das","year":"2024","journal-title":"Transl. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, N., and Zhang, C. (2024). Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063086"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sinha, S.K., and Nicholas, S.B. (2023). Pathomechanisms of Diabetic Kidney Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12237349"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4093\/dmj.2021.0329","article-title":"Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease","volume":"46","author":"Jung","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2019.07.005","article-title":"Mitochondrial dysfunction in diabetic kidney disease","volume":"496","author":"Wei","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: Translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chang, J., Yan, J., Li, X., Liu, N., Zheng, R., and Zhong, Y. (2021). Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease. Front. Med., 8.","DOI":"10.3389\/fmed.2021.661076"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.dsx.2018.11.054","article-title":"Diabetic nephropathy: An update on pathogenesis and drug development","volume":"13","author":"VR","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.jrn.2023.05.006","article-title":"Effects of Vitamin D Supplementation in Diabetic Kidney Disease: A Systematic Review","volume":"33","author":"Ramalho","year":"2023","journal-title":"J. Ren. Nutr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Darenskaya, M., Kolesnikov, S., Semenova, N., and Kolesnikova, L. (2023). Diabetic Nephropathy: Significance of Determining Oxidative Stress and Opportunities for Antioxidant Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512378"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.17219\/acem\/104534","article-title":"Glomerular podocytes in diabetic renal disease","volume":"28","author":"Konieczny","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Patel, D.M., Bose, M., and Cooper, M.E. (2020). Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062218"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, Z., Liu, J., Wang, W., An, X., Luo, L., Yu, D., and Sun, W. (2023). Epigenetic modification in diabetic kidney disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1133970"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rico-Fontalvo, J., Aroca-Mart\u00ednez, G., Daza-Arnedo, R., Cabrales, J., Rodr\u00edguez-Yanez, T., Cardona-Blanco, M., Montejo-Hern\u00e1ndez, J., Rodelo Barrios, D., Pati\u00f1o-Pati\u00f1o, J., and Osorio Rodr\u00edguez, E. (2023). Novel Biomarkers of Diabetic Kidney Disease. Biomolecules, 13.","DOI":"10.3390\/biom13040633"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s11255-022-03354-7","article-title":"Novel biomarkers for prognosticating diabetic kidney disease progression","volume":"55","author":"Swaminathan","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Argyropoulos, C.P., Chen, S.S., Ng, Y.H., Roumelioti, M.E., Shaffi, K., Singh, P.P., and Tzamaloukas, A.H. (2017). Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00073"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.metabol.2016.02.012","article-title":"Beta-2-microglobulin (B2M) expression in the urinary sediment correlates with clinical markers of kidney disease in patients with type 1 diabetes","volume":"65","author":"Monteiro","year":"2016","journal-title":"Metabolism"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4093171","DOI":"10.1155\/2017\/4093171","article-title":"Clinical Utility of Urinary \u03b22-Microglobulin in Detection of Early Nephropathy in African Diabetes Mellitus Patients","volume":"2017","author":"Ekrikpo","year":"2017","journal-title":"Int. J. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/13543784.2020.1811231","article-title":"Novel therapeutic agents for the treatment of diabetic kidney disease","volume":"29","author":"Hartman","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_26","first-page":"154","article-title":"Management of diabetic renal disease","volume":"3","author":"Eboh","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bayne, S., LeFevre, J., Olstinske, K., Ravindran, S., and Munusamy, S. (2024). Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease. Adv. Biol., 8.","DOI":"10.1002\/adbi.202300496"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jcp.30621","article-title":"Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease","volume":"237","author":"Ravindran","year":"2022","journal-title":"J. Cell Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12964-024-01914-1","article-title":"Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C.S., Nishii, N., and Yamada, H. (2014). Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100777"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bph.12269","article-title":"Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db\/db mice","volume":"170","author":"Nagata","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Stanigut, A.M., Pana, C., Enciu, M., Deacu, M., Cimpineanu, B., and Tuta, L.A. (2022). Hypoxia-Inducible Factors and Diabetic Kidney Disease-How Deep Can We Go?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810413"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4103\/jfmpc.jfmpc_2249_21","article-title":"\u2018Oxidative stress\u2019-A new target in the management of diabetes mellitus","volume":"12","author":"Das","year":"2023","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, P., Lozano, P., Ros, G., and Solano, F. (2023). Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119352"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12964-024-01502-3","article-title":"Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: An updated review","volume":"22","author":"Hu","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jdiacomp.2016.10.020","article-title":"VEGF and the diabetic kidney: More than too much of a good thing","volume":"31","author":"Majumder","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"F287","DOI":"10.1152\/ajprenal.00533.2014","article-title":"Glomerular endothelial cell injury and cross talk in diabetic kidney disease","volume":"308","author":"Fu","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Buchanan, S., Combet, E., Stenvinkel, P., and Shiels, P.G. (2020). Klotho, Aging, and the Failing Kidney. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00560"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Piwkowska, A., Zdrojewski, \u0141., Heleniak, Z., and D\u0119bska-\u015alizie\u0144, A. (2022). Novel Markers in Diabetic Kidney Disease-Current State and Perspectives. Diagnostics, 12.","DOI":"10.3390\/diagnostics12051205"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tang, A., Zhang, Y., Wu, L., Lin, Y., Lv, L., Zhao, L., Xu, B., Huang, Y., and Li, M. (2023). Klotho\u2019s impact on diabetic nephropathy and its emerging connection to diabetic retinopathy. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1180169"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ghosal, S., and Sinha, B. (2023). Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1114894"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1111\/dom.15773","article-title":"The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease","volume":"26","author":"Fantaye","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41371-020-00467-3","article-title":"The mineralocorticoid receptor-an emerging player in metabolic syndrome?","volume":"35","author":"Thuzar","year":"2021","journal-title":"J. Hum. Hypertens."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41440-018-0034-4","article-title":"Hypertension with diabetes mellitus: Physiology and pathology","volume":"41","author":"Ohishi","year":"2018","journal-title":"Hypertens. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yang, M., Luo, S., Yang, J., Chen, W., He, L., Liu, D., Zhao, L., and Wang, X. (2022). Bone-kidney axis: A potential therapeutic target for diabetic nephropathy. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.996776"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Takashi, Y., and Kawanami, D. (2022). The Role of Bone-Derived Hormones in Glucose Metabolism, Diabetic Kidney Disease, and Cardiovascular Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042376"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Li, Y., Gu, Z., Wang, J., Wang, Y., Chen, X., and Dong, B. (2022). The Emerging Role of Bone-Derived Hormones in Diabetes Mellitus and Diabetic Kidney Disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.938830"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cca.2022.05.001","article-title":"Microparticles in diabetic kidney disease","volume":"531","author":"Kanakalakshmi","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.11005\/jbm.2020.27.3.207","article-title":"Bone Mineral Density in Diabetes Mellitus Foot Patients for Prediction of Diabetic Neuropathic Osteoarthropathic Fracture","volume":"27","author":"Cho","year":"2020","journal-title":"J. Bone Metab."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Noh, J.Y., Yang, Y., and Jung, H. (2020). Molecular Mechanisms and Emerging Therapeutics for Osteoporosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207623"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000516911","article-title":"From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options","volume":"46","author":"Sharma","year":"2021","journal-title":"Kidney Blood Press. Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Shu, H., Zhang, Z., Liu, J., Chen, P., Yang, C., Wu, Y., Wu, D., Cao, Y., Chu, Y., and Li, L. (2023). Circular RNAs: An emerging precise weapon for diabetic nephropathy diagnosis and therapy. Biomed. Pharmacother., 168.","DOI":"10.1016\/j.biopha.2023.115818"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Garcia-Fernandez, N., Jacobs-Cach\u00e1, C., Mora-Guti\u00e9rrez, J.M., Vergara, A., Orbe, J., and Soler, M.J. (2020). Matrix Metalloproteinases in Diabetic Kidney Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020472"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.matbio.2018.03.007","article-title":"Connective tissue growth factor (CTGF) from basics to clinics","volume":"68\u201369","author":"Ramazani","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-018-0070-0","article-title":"CTGF in kidney fibrosis and glomerulonephritis","volume":"38","author":"Toda","year":"2018","journal-title":"Inflamm. Regen."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00011-018-1200-5","article-title":"The role of osteopontin in kidney diseases","volume":"68","author":"Kaleta","year":"2019","journal-title":"Inflamm. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sinha, S.K., Mellody, M., Carpio, M.B., Damoiseaux, R., and Nicholas, S.B. (2023). Osteopontin as a Biomarker in Chronic Kidney Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051356"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wagner, M., Ashby, D.R., Kurtz, C., Alam, A., Busbridge, M., Raff, U., Zimmermann, J., Heuschmann, P.U., Wanner, C., and Schramm, L. (2015). Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123072"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ackd.2019.04.005","article-title":"Hepcidin","volume":"26","author":"Agarwal","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_64","first-page":"133","article-title":"The determinants of hepcidin level in chronic kidney disease and hemodialysis Saudi patients","volume":"3","author":"Ali","year":"2014","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"ref_65","first-page":"108","article-title":"Hepcidin in chronic kidney disease: Not an anaemia management tool, but promising as a cardiovascular biomarker","volume":"73","author":"Grooteman","year":"2015","journal-title":"Neth. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1093\/ndt\/gfr410","article-title":"Hepcidin: Another culprit for complications in patients with chronic kidney disease?","volume":"26","author":"Nakanishi","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.2023.4480","article-title":"Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial","volume":"329","author":"Lawler","year":"2023","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Maiti, A.K. (2021). Development of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189985"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Khan, N.U., Lin, J., Liu, X., Li, H., Lu, W., Zhong, Z., Zhang, H., Waqas, M., and Shen, L. (2020). Insights into predicting diabetic nephropathy using urinary biomarkers. Biochim. Biophys. Acta Proteins Proteom., 1868.","DOI":"10.1016\/j.bbapap.2020.140475"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s12020-014-0437-1","article-title":"Inflammation in diabetic nephropathy: Moving toward clinical biomarkers and targets for treatment","volume":"48","author":"Barutta","year":"2015","journal-title":"Endocrine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2478\/prilozi-2020-0002","article-title":"Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go","volume":"40","author":"Ntrinias","year":"2019","journal-title":"Prilozi"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3232848","DOI":"10.1155\/2017\/3232848","article-title":"Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus","volume":"2017","author":"Dande","year":"2017","journal-title":"J. Diabetes Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/gfab167","article-title":"Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease","volume":"38","author":"Ortiz","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2337\/dc19-1580","article-title":"Superior Long-term Survival for Simultaneous Pancreas-Kidney Transplantation as Renal Replacement Therapy: 30-Year Follow-up of a Nationwide Cohort","volume":"43","author":"Esmeijer","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kuo, F.C., Chao, C.T., and Lin, S.H. (2022). The Dynamics and Plasticity of Epigenetics in Diabetic Kidney Disease: Therapeutic Applications Vis-\u00e0-Vis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020843"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e3809","DOI":"10.1002\/dmrr.3809","article-title":"The role of long non-coding RNAs in the development of diabetic kidney disease and the involved clinical application","volume":"40","author":"Hou","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mao, Z.H., Gao, Z.X., Liu, D.W., Liu, Z.S., and Wu, P. (2023). Gut microbiota and its metabolites-molecular mechanisms and management strategies in diabetic kidney disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1124704"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000529709","article-title":"Exosomes in Diabetic Kidney Disease","volume":"9","author":"Wen","year":"2023","journal-title":"Kidney Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"154834","DOI":"10.1016\/j.metabol.2021.154834","article-title":"Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy","volume":"122","author":"Chen","year":"2021","journal-title":"Metabolism"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3960857","DOI":"10.1155\/2020\/3960857","article-title":"Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy","volume":"2020","author":"Lv","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Li, J., Zheng, S., Ma, C., Chen, X., Li, X., Li, S., Wang, P., Chen, P., Wang, Z., and Li, W. (2023). Research progress on exosomes in podocyte injury associated with diabetic kidney disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1129884"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Han, Y.Z., Du, B.X., Zhu, X.Y., Wang, Y.Z., Zheng, H.J., and Liu, W.J. (2024). Lipid metabolism disorder in diabetic kidney disease. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1336402"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1900\/RDS.2015.12.110","article-title":"Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis","volume":"12","author":"Tziomalos","year":"2015","journal-title":"Rev. Diabet. Stud."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00109-024-02432-w","article-title":"The therapeutic effect of mesenchymal stem cells in diabetic kidney disease","volume":"102","author":"Habiba","year":"2024","journal-title":"J. Mol. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:19Z","timestamp":1759919659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030727"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030727","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}